New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
16:28 EDTMCD, TKMR, NVDA, POST, IRGOn The Fly: Closing Wrap
Stocks began the session in positive territory despite President Obama authorizing air strikes against the Islamic State militant group in northern Iraq in conjunction with a humanitarian effort. The early move higher stalled but the market then moved higher as reports confirmed that Russian military aircraft exercises near the Ukraine border had ended, as planned. ECONOMIC EVENTS: In the U.S., productivity growth rose 2.5% in the second quarter, beating expectations for a rise of 1.6%. Second quarter unit labor costs, however, only increased 0.6%, which was below the 1% consensus forecast. Wholesale inventories increased 0.3% in June, and sales were up 0.2%, which were both below expectations. COMPANY NEWS: Shares of McDonald's (MCD) were fractionally higher despite the company reporting that its comparable store sales fell 2.5% in July, which was significantly worse than expected. The fast food giant stated that its U.S. comparable sales were down 3.2% in the month compared to the same month of last year and that comp sales in Asia/Pacific, Middle East and Africa dropped 7.3%. The APMEA region's comparable sales decline reflects the impact of food quality and safety issues at a supplier to McDonald's and other food companies in China which caused a "significant negative impact" to results in China, Japan and certain other markets, the company noted. As a result of the China supplier issue, the company's previously issued global comparable sales forecast for 2014 is now at risk, McDonald's added. MAJOR MOVERS: Among the notable gainers was chip maker NVIDIA (NVDA), which rose $1.54, or 8.82%, to $19.00 after the company’s second quarter profit and third quarter revenue outlook surpassed analysts’ consensus estimates. Also higher was small-cap Tekmira Pharmaceuticals (TKMR), which jumped $6.43, or 45.06%, to $20.70 after announcing that the FDA has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New Drug Application to a partial clinical hold. Among the noteworthy losers was cereal maker Post Holdings (POST), which fell $7.08, or 15.91%, to $37.43 and was downgraded to Neutral from Buy at SunTrust after the company reported an adjusted net loss for its third quarter and agreed to acquire American Blanching Company for $128M. Also lower were shares of Ignite Restaurant (IRG), the owner of the Joe’s Crab Shack and Macaroni Grill brands, which fell $4.33, or 34.98%, to $8.05 after reporting second quarter results that missed analysts' expectations and having its shares downgraded at Raymond James and CL King. INDEXES: The Dow advanced 185.66, or 1.13%, to 16,553.93, the Nasdaq gained 35.93, or 0.83%, to 4,370.90, and the S&P 500 rose 22.02, or 1.15%, to 1,931.59.
News For MCD;TKMR;NVDA;POST;IRG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 16, 2014
06:21 EDTMCDMcDonald's rehires former U.S. executive, WSJ reports
Subscribe for More Information
October 15, 2014
15:34 EDTTKMRTekmira TKM-HBN preclinical study shows 'knockdown of HBV surface antigen'
Subscribe for More Information
10:49 EDTTKMREbola linked names rise again amid broader market sell-off
Subscribe for More Information
09:57 EDTTKMRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:58 EDTTKMRTekmira volatility up, 2nd Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 14, 2014
11:34 EDTPOSTMitsubishi Corp., Post, others vie for Bumble Bee, Bloomberg says
Subscribe for More Information
11:19 EDTTKMRNIH says several potential Ebola treatments under development
Subscribe for More Information
10:10 EDTTKMRNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
09:04 EDTTKMRChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
05:40 EDTTKMRTekmira partner Alnylam reports positive clinical data for Patisiran study
Tekmira Pharmaceuticals (TKMR) reported that Alnylam Pharmaceuticals (ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension, or OLE, study in patients with Familial Amyloidotic Polyneuropathy, or FAP. Patisiran is an RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, which is enabled by Tekmira's lipid nanoparticle, or LNP, technology. Alnylam presented data at the American Neurological Association's 2014 Annual Meeting. Results showed a mean 0.95 point decrease in modified Neuropathy Impairment Score at six months in 19 patients with mNIS+7 data available for the current analysis. This decrease in neuropathy progression compares favorably with the 7 to 10 point increase in mNIS+7 at six months that can be estimated from historical data sets in untreated FAP patients with similar baseline characteristics.
October 13, 2014
14:06 EDTMCDMcDonald's to answer questions about food, AP reports
Subscribe for More Information
07:12 EDTTKMROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
07:11 EDTTKMRTekmira volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
07:09 EDTNVDANVIDIA added to Best Ideas list at JMP Securities
Subscribe for More Information
October 12, 2014
19:26 EDTTKMRPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTTKMRCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTTKMRNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTTKMRTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
October 10, 2014
17:03 EDTPOSTPost Holdings names Jeff Zadoks CFO
Subscribe for More Information
10:54 EDTTKMRMapp looking to up production of experimental Ebola treatment, WSJ says
Mapp Biopharmaceutical is aiming to broaden the manufacturing of its experimental Ebola treatment, ZMapp, according to The Wall Street Journal, citing comments from the company. Mapp said that the treatment was given to a few infected individuals prior to supplies running out two months ago. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use